Is Monopar Therapeutics profitable?

Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.

Where does Monopar Therapeutics's income statement data come from?

Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Monopar Therapeutics MNPR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$0—	$0—	$0—	——
Research and development	$9.9M-23.8%	$13.01M+132%	$5.6M-26.2%	$7.59M+16.9%
General and administrative	$6.8M+115%	$3.16M-2.3%	$3.23M+9.7%	$2.95M+11.8%
Total operating expenses	$16.7M+3.4%	$16.16M+83.0%	$8.83M-16.2%	$10.54M+15.4%
Operating income	-$16.7M-3.4%	-$16.16M-83.0%	-$8.83M+16.2%	-$10.54M-15.4%
Net income	-$13.72M+12.0%	-$15.59M-85.5%	-$8.4M+20.1%	-$10.52M-15.5%
EBIT	-$16.7M-3.4%	-$16.16M-83.0%	-$8.83M+16.2%	-$10.54M-15.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Monopar Therapeutics profitable?: Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
Where does Monopar Therapeutics's income statement data come from?: Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.